active immunotherapy


Also found in: Medical.

active immunotherapy

[¦ak·tiv ¦im·yə·nō′ther·ə·pē]
(immunology)
A type of immunotherapy that attempts to stimulate the host's intrinsic immune response to the tumor, either nonspecifically or specifically.
References in periodicals archive ?
Joseph Kim, Inovio's President and CEO, said, "As a leader in active immunotherapy for cancer with its lead program in phase 3, Inovio is pleased to report on promising phase 1b clinical trial data of our prostate cancer therapy INO-5150.
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy.
This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein.
Created in 1993, Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases.
Polycap (for prevention and treatment of cardiovascular diseases), Risorine (for treatment of tuberculosis) and Mycidac-C, the world's first active immunotherapy for lung cancer, are three innovative drugs that we have developed.
This is a first in the class active immunotherapy as well as drug targeting Desmocollin-3.
They describe strategies of passive and active immunotherapy, improving immunotherapeutic responses using combinations of agents for immunochemotherapy, and targeting strategies to defeat immune suppression.
Our company is focused on active immunotherapy, which basically means stimulating the immune system to fight disease.
12) Depending on the patient's response, a doubling of medication needed because of poor control may well be more costly than active immunotherapy, especially as the injection frequency decreases.
Pharmexa, headquartered in Horsholm, Denmark, is a development stage company in the field of active immunotherapy.
Open sessions will focus on today's hottest oncology issues along with updated information on new drugs, evidence-based practice, patient teaching, secondary cancers, acute leukemia, hereditary cancers, genetics, active immunotherapy, multisite research, symptom management, pain management, end-of-life care, targeted and biologic therapies, healthcare advocacy, and nurturing caregivers.
Genitope Corporation's lead product candidate, MyVax personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.